5 Nov 2014 16:20
For immediate release | 5 November 2014 |
ABCAM PLC
("Abcam" or "the Company")
Director dealing: LTIP
Cambridge, UK: Abcam plc (AIM: ABC), a global leader in the supply of protein research tools, announces that on 4 November 2014 the Remuneration Committee granted the following share awards in the form of Nil Cost Options or Conditional Shares (the "Award") to the Directors of the Company under the Abcam plc Long-Term Incentive Plan (the "LTIP"):
Director | Number of 0.2 pence Ordinary Shares subject to the LTIP Award
|
Alan Hirzel | 38,359* |
Jim Warwick | 31,610 |
Jeff Iliffe | 34,670 |
* The award made to Alan Hirzel is in the form of conditional shares which will be delivered following vesting.
The Awards will vest in three years' time subject to continued employment and subject to a performance condition based on growth in earnings per share.
For further information please contact:
Abcam | + 44 (0) 1223 696 000 |
Jeff Iliffe, Chief Financial Officer
| |
Numis Securities - Nominated Adviser & Joint Broker | + 44 (0) 20 7260 1000 |
Michael Meade - Nominated Adviser | |
James Black - Corporate Broking
| |
Peel Hunt LLP - Joint Broker | + 44 (0) 20 7418 8900 |
Clare Terlouw / Jock Maxwell MacDonald
| |
Brunswick | + 44 (0) 20 7404 5959 |
Justine Mcllroy / Robin Wrench |
Notes for editors:
About Abcam plc
Abcam plc is a leading provider of life science research tools and services, with a wide range of products and expert technical support, enabling scientists to analyse living cells at the molecular level and improving the understanding of health and disease.
Abcam is committed to providing scientists with an extensive choice of reagents and tools, with the most comprehensive, honest and up-to-date datasheets and customer reviews, fast delivery and helpful customer service & technical support. The Company's catalogue evolves with scientific research trends and is growing each year to provide customers with products to meet their research needs. The range now includes primary and secondary antibodies, proteins, peptides, lysates, biochemicals, immunoassays and other kits. Abcam also supports its customers by hosting a range of global scientific events, forums and webinars, providing opportunities for scientists to get together and present their work.
Headquartered in Cambridge, UK, Abcam has eight global subsidiary offices enabling local services, multi-language support and sells to over 100 countries. The Company was founded in 1998, and now employs over 740 people. Abcam was admitted to AIM in 2005 (AIM: ABC).
To find out more, please visit www.abcamplc.com